The announcement of a mixed shelf offering of up to $250 million by Aquestive Therapeutics is likely to dilute existing shareholders' equity, leading to a negative short-term impact on the stock price. This type of equity action often results in an immediate negative reaction from the market as investors adjust to the potential for dilution and the implications it has for the value of their holdings.